Comparing PFE's and BMY's Immunology Drugs - Market Realist

Comparing PFE's and BMY's Immunology Drugs  Market Realist

Pfizer's (PFE) commercialized JAK (Janus kinase) inhibitor, Xeljanz, is approved for treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.



Comments

Popular posts from this blog

Epstein-Barr virus and autoimmune diseases

Chronic Lyme arthritis: A mystery solved?

Fibromyalgia — Latest Stories — Pain News Network